Mangoceuticals (MGRX) EPS (Weighted Average and Diluted) (2023 - 2026)

Mangoceuticals has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.22 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.22, up 80.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.49 (up 64.1% YoY), and the FY2025 annual result was -$2.17, up 54.79% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.22 for Q1 2026 at Mangoceuticals, down from -$0.01 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q4 2025 to a low of -$1.9 in Q4 2023.
• The 4-year median for EPS (Weighted Average and Diluted) is -$0.69 (2025), against an average of -$0.85.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 878.57% in 2024 and jumped 98.08% in 2025, its largest moves.
• Mangoceuticals' EPS (Weighted Average and Diluted) stood at -$1.9 in 2023, then surged by 72.63% to -$0.52 in 2024, then surged by 98.08% to -$0.01 in 2025, then tumbled by 2100.0% to -$0.22 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.22 (Q1 2026), -$0.01 (Q4 2025), and -$0.69 (Q3 2025), per Business Quant data.